These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7837725)

  • 1. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review].
    Amitani R; Kuze F
    Kekkaku; 1994 Nov; 69(11):711-7. PubMed ID: 7837725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
    Kawahara S; Nagare H
    Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
    Mizutani S
    Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antimycobacterial activities of rifamycin derivatives].
    Kuze F
    Kekkaku; 1991 Oct; 66(10):679-85. PubMed ID: 1960916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current status and perspectives on the development of rifamycin derivative antibiotics].
    Hidaka T
    Kekkaku; 1999 Jan; 74(1):53-61. PubMed ID: 10067056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expectation of new antituberculous drugs and targeting therapy for treatment of mycobacterial infections].
    Tomioka H
    Kekkaku; 1993 Nov; 68(11):723-30. PubMed ID: 8264129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of mycobacterial infections in patients with HIV/AIDS].
    Pulido F; Iribarren JA; Kindelan JM; Moreno S
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():20-8. PubMed ID: 9859616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
    Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
    Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimycobacterial drugs.
    Heifets LB
    Semin Respir Infect; 1994 Jun; 9(2):84-103. PubMed ID: 7973175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antimycobacterial agents.
    Cynamon MH; Klemens SP
    Clin Chest Med; 1989 Sep; 10(3):355-64. PubMed ID: 2505963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.
    Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC
    Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of non-tuberculous pulmonary mycobacteriosis].
    Sakatani M; Nakajima Y
    Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with rifabutin in the treatment of mycobacterial infections.
    De Cian W; Sassella D; Wynne BA
    Scand J Infect Dis Suppl; 1995; 98():22-6. PubMed ID: 8867175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rifabutine in the treatment of mycobacterial infections resistant to rifampicin. Preliminary results. Group for the Study and Treatment of Resistant Mycobacterial Infections (GETIM)].
    Rev Mal Respir; 1989; 6(4):335-42. PubMed ID: 2552547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.